Diabetes group recommends against compounded GLP-1s

Becker's Healthcare December 2, 2024
Mackenzie Bean

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care.

The association cited uncertainty over the content of the compounded medications, as well as their safety, quality and effectiveness.

“Compounded products are not FDA-approved and do not undergo FDA review for safety, quality or effectiveness standards. As a result, these products may present elevated risks to individuals,” the ADA wrote in its guidance.

If a medication is unavailable, the ADA recommends switching to a different FDA-approved drug to support patients’ glucose-lowering, weight management, and cardiovascular or kidney risk reduction goals. Clinicians should reassess the appropriateness of resuming the original FDA-approved medication...

Today's Sponsors

Today's Sponsor